## MRNA: Moderna, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.6% below STRENGTH zone (3.0-6.0%); PEG 2.44 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-15.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($28.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma**
- Source: The Coloradoan | 20251229T110842 | Bullish | Relevance: 100%
- Moderna has initiated a Phase 1/2 study of mRNA-2808, an investigational mRNA-based T-cell engager (TCE), with the first patient dosed for relapsed or refractory multiple myeloma (RRMM). This multiplexed therapy aims to address tumor heterogeneity and resistance mechanisms by encoding three TCEs targeting validated myeloma-associated antigens. The study, NCT07116616, is evaluating the safety and tolerability of mRNA-2808 in RRMM patients aged 18 and older.

**2. Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference**
- Source: South Bend Tribune | 20251229T110842 | Neutral | Relevance: 100%
- Moderna, Inc. announced its participation in the 44th annual J.P. Morgan Healthcare Conference, scheduled for Monday, January 12th, at 7:30 p.m. ET. A live webcast of the presentation will be available on the Investors section of Moderna's website, with a replay archived for at least 30 days. The company, a leader in mRNA medicine, focuses on developing vaccines and therapeutics for various diseases.

**3. CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate**
- Source: Palm Beach Daily News | 20251228T190831 | Bullish | Relevance: 100%
- The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase 3 clinical trial for Moderna's mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. This funding aims to accelerate the vaccine's licensure and enhance global pandemic preparedness, marking the first mRNA-based vaccine for pandemic influenza to enter a pivotal trial. Moderna has committed to allocating 20% of its H5 pandemic vaccine manufacturing capacity for timely and affordable supply to low- and middle-income countries if the vaccine is licensed.

**4. Moderna Stock (MRNA) News Today: Market Closed Sunday as Investors Weigh Friday Slide, Analyst Targets, and 2026 Catalysts**
- Source: ts2.tech | 20251228T114640 | Neutral | Relevance: 100%
- Moderna (NASDAQ: MRNA) stock experienced a slide on Friday, closing the week at $31.20, down 4.73%. Investors are now evaluating this pullback against broader company efforts to expand beyond COVID-19 vaccines into a multi-product platform, with upcoming catalysts in 2026 including Phase 3 trials and presentations at the J.P. Morgan Healthcare Conference in January. Analyst sentiment remains mixed, with a "Reduce" consensus and a wide range of price targets, reflecting the company's transition and execution risks.

**5. TB Alternative Assets Ltd. Sells 602,072 Shares of Moderna, Inc. $MRNA**
- Source: MarketBeat | 20251228T114440 | Somewhat-Bearish | Relevance: 100%
- TB Alternative Assets Ltd. significantly reduced its stake in Moderna, Inc. by selling over 600,000 shares, cutting its position by 47.7% to 658,881 shares. This move places Moderna as approximately 2.5% of the fund's portfolio. Despite other large institutional increases, Moderna faces weak fundamentals, including a 45.4% year-over-year revenue drop and a consensus "Reduce" rating from analysts with an average price target below its current trading price.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $28 | $30 | -7% |
| 2025-12-12 | Jefferies | $30 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-12 | Jefferies | init | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.26M) |
| Sells | 11 ($0.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-1.2%)
- Blackrock Inc.: 7.6% (+3.2%)
- BAILLIE GIFFORD & CO: 5.6% (-1.1%)
- State Street Corpora: 4.4% (-0.9%)
- FMR, LLC: 3.1% (-37.4%)

### Key Risks

1. High short interest (21.7%, 7.0 days to cover): squeeze risk or crowded bearish bet.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.44 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.9x), low leverage (D/E 0.30). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $12.2B |
| Beta | 1.11 |
| 52W Range | $22.28 - $48.92 |
| Short Interest | 21.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.44 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 13.1% to -2.6% (-15.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.6pp (needs >3.0% for momentum thesis). Underperforming sector by 3.6pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.62% (CS: 10) | Weak |
| RSI_14 | 58.1 | Neutral |
| MACD Histogram | 0.12 | Bullish |
| vs SMA20 | 1.059x | Above |
| vs SMA50 | 1.154x | Above |
| vs SMA200 | 1.135x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $31.15
- **Stop Loss:** $28.07 (9.9% risk)
- **Target:** $34.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 448
- **Position Value:** $13,955.20
- **Portfolio %:** 13.96%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $-2.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-2.18 | $-0.51 | +76.6% |
| 2025Q2 | $-2.97 | $-2.13 | +28.3% |
| 2025Q1 | $-3.18 | $-2.52 | +20.7% |
| 2024Q4 | $-2.76 | $-2.91 | -5.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*